The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

Neon Hospital20 enrolled

Overview

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Macular Edema

Interventions

Subconjunctival bevacizumab (Altuzan)DRUG

Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Having diffuse diabetic macular edema persisted at least 1 month * No intravitreal injection in last 3 months. * No retinal laser photocoagulation in last 6 months * Not have any other macular disease causing macular edema Exclusion Criteria: * Having ischemic macula * Intravitreal injection in last 3 months. * Retinal laser photocoagulation in last 6 months * Have any other macular disease causing macular edema

Outcomes

Primary Outcomes

Central Macular Thickness

Time frame: one year (between May 2015 and May 2016)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.